Ramping it up: RAMP1 and the implications for migraine

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 687-690

  Russo, Andrew F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; OLCEGEPANT; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; TRIPTAN DERIVATIVE;

ANALGESIA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG MECHANISM; EDITORIAL; GENE MUTATION; GENE TRANSFER; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; MIGRAINE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SYMPTOM;

CALCITONIN GENE-RELATED PEPTIDE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MIGRAINE DISORDERS;

EID: 34548099668     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.687     Document Type: Editorial

References (26)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M: Prevalence and burden of migraine in the United States deta from the American Migraine Study II. Headache 4l, 646-657 (2001).
2. Goadsby PJ, Lipton RB, Ferrari MD: Migraine - current understanding and treatment. N. Engl. J Med. 346, 257-270 (2002).
3. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR: Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur. J. Pharmacol. 500, 315-330 (2004).
4. Edvinsson L: Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24, 611-622 (2004).
5. Goadsby PJ: Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin. Emerg, Drugs 11, 419-427 (2006).
6. Marquez de Prado B, Ruseo AF: CGRP receptor antagonists a new frontier of anti-migraine medications Drug Discov. Today: Ther. Strategies 3, 593-597 (2006).
7. Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurology 28, 181-197 (1990).
8. Juhasz G, Zsombok T, Modos EA et al.: NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106, 461-470 (2003).
9. Lassen LH, Haderslev PA, Jacobsen VB, Ivenan HK, Sperling B, Olesen J: CGRP may play a causative role in migraine, Cephalalgia 22, 54-61 (2002).
10. l0 Olesen J, Diener HC, Husstedt IW et al.: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110 (2004).
11. Poyner DR, Sexton PM, Marshall I et al.: International Union of Pharmacology XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 54, 233-246 (2002).
12. McLatchie LM, Fraser NJ, Main et al.: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333-339 (1998).
13. Hay DL, Poyner DR, Saxton PM: GPCR modulation by RAMPs. Pharmacol. Ther. 109, 173-197 (2006).
14. Evans BN, Rosenblatt MI, Mnayer LO, Oliver KR, Dickerson IM: CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors, J. Biol. Chem. 275, 31438-31443 (2000).
15. Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 84, 903-934 (2004).
16. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J: No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann. Neurol. 58, 561-568 (2005).
17. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther. 77, 202-213 (2005).
18. Levy D, Burstein R, Strassman AM: Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine Ann. Neurol. 58, 698-705 (2005).
19. Zhang Z, Dickerson IM, Russo AF: Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology 147, 1932-1940 (2006).
20. Zhang Z, Winborn CS, Marquez de Prado, B, Russo AF: Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci. 27, 2693-2703 (2007).
21. Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL: Tumor necrosis factor-α stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons, J. Neurochem. 96, 65-77 (2006).
22. Durham PL: CGRP-receptor antagonists - a fresh approach to migraine therapy? N. Engl. J. Med. 350, 1073-1075 (2004).
23. Bergerot A, Holland PR, Akerman S et al.: Animal models of migraine: looking at the component parts of a complex disorder. Eur. J. Neurosci. 24, 1517-1534 (2006).
24. Ma W, Chabot JG, Quirion R; A role for adrenomedullin as a pain-related peptide in the rat. Proc. Natl Acad. Sci. USA 103, 16027-16032 (2006).
25. Gardner KL: Genetics migraine: an update, Headache 46 (Suppl. 1), S19-S24 (2006).
26. Loder E, Harrington MG, Cutrer M, Sandor P, de Vries B: Selected confirmed, probable, and exploratory migraine biomarkers. Headaches 46, 1108-1127 (2006).